Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management.
作者： Vidyasagar Ramappa , Guruprasad P. Aithal
DOI: 10.1016/J.JCEH.2012.12.001
关键词:
摘要: … resolve these are thought to represent ‘adaptation’ 107 rather than hepatotoxicity; potential mechanisms underlying the former phenomenon are discussed in the literature. The Seattle-…
sci-hub.se 参考文章(115)
JAIME R. UNGO, DENIS JONES, DAVID ASHKIN, ELENA S. HOLLENDER, DAVID BERNSTEIN, ANTHONY P. ALBANESE, ARTHUR E. PITCHENIK, Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus. American Journal of Respiratory and Critical Care Medicine. ,vol. 157, pp. 1871- 1876 ,(1998) , 10.1164/AJRCCM.157.6.9711039
Surendra K. Sharma, Rohit Singla, Pawan Sarda, Alladi Mohan, Govind Makharia, Arvind Jayaswal, Vishnubhatla Sreenivas, Sarman Singh, Safety of 3 Different Reintroduction Regimens of Antituberculosis Drugs after Development of Antituberculosis Treatment–Induced Hepatotoxicity Clinical Infectious Diseases. ,vol. 50, pp. 833- 839 ,(2010) , 10.1086/650576
Jacques Grosset, Stephanie Leventis, Adverse Effects of Rifampin Clinical Infectious Diseases. ,vol. 5, ,(1983) , 10.1093/CLINIDS/5.SUPPLEMENT_3.S440
Philip C. Burcham, Molecular Basis for Adaptive Responses during Chemically Induced Hepatotoxicity Toxicological Sciences. ,vol. 89, pp. 349- 351 ,(2006) , 10.1093/TOXSCI/KFJ059
Jussi J. Saukkonen, David L. Cohn, Robert M. Jasmer, Steven Schenker, John A. Jereb, Charles M. Nolan, Charles A. Peloquin, Fred M. Gordin, David Nunes, Dorothy B. Strader, John Bernardo, Raman Venkataramanan, Timothy R. Sterling, An official ATS statement: hepatotoxicity of antituberculosis therapy. American Journal of Respiratory and Critical Care Medicine. ,vol. 174, pp. 935- 952 ,(2006) , 10.1164/RCCM.200510-1666ST
MI Prince, AD Burt, DEJ Jones, Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis Gut. ,vol. 50, pp. 436- 439 ,(2002) , 10.1136/GUT.50.3.436
A. B. Younossian, T. Rochat, J-P. Ketterer, J. Wacker, J-P. Janssens, High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis European Respiratory Journal. ,vol. 26, pp. 462- 464 ,(2005) , 10.1183/09031936.05.00006205
, A Double-blind Placebo-controlled Clinical Trial of Three Antituberculosis Chemoprophylaxis Regimens in Patients with Silicosis in Hong Kong The American review of respiratory disease. ,vol. 145, pp. 36- 41 ,(2012) , 10.1164/AJRCCM/145.1.36
P-Y. Wang, S-Y. Xie, Q. Hao, C. Zhang, B-F. Jiang, NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. International Journal of Tuberculosis and Lung Disease. ,vol. 16, pp. 589- 595 ,(2012) , 10.5588/IJTLD.11.0377
L.T. Tanoue, Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection—United States, 2003 Yearbook of Pulmonary Disease. ,vol. 2006, pp. 303- 304 ,(2006) , 10.1016/S8756-3452(08)70243-3